Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease

NCT07328451 is registered in ClinicalTrials.gov with Denali Therapeutics Inc. as lead sponsor.

NCT NCT07328451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07328451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
Lead sponsor
Denali Therapeutics Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
January 30, 2026
Completion date
February 28, 2027
Enrollment
68 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, early onset